A5070876458- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Academic Publishing and Open Access
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Multiple Myeloma Research and Treatments
- Social Media in Health Education
- Lung Cancer Research Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Thyroid Cancer Diagnosis and Treatment
- Architecture, Art, Education
- Global Health and Surgery
- Lung Cancer Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Global Cancer Incidence and Screening
- Architecture and Computational Design
- CNS Lymphoma Diagnosis and Treatment
- Extracellular vesicles in disease
University of California, Irvine
2024
Norton Healthcare
2024
West Virginia University
2014-2015
PURPOSE Sacituzumab govitecan (SG) is a Trop-2–directed antibody-drug conjugate with an SN-38 payload, approved for patients locally advanced (LA) or metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and checkpoint inhibitor (CPI). Here, we report results from Cohort 2 of TROPHY-U-01 trial, evaluating the efficacy safety SG in mUC. METHODS (ClinicalTrials.gov identifier: NCT03547973 ) multicohort, open-label phase II study. includes LA mUC have had...
The emergence of serine-threonine small molecule, multi-targeted kinase inhibitors over the past decade is greatly impacting therapeutic armamentarium for numerous malignancies, especially thyroid carcinoma. Chief among them are a class agents referred to as vascular endothelial growth factor signal pathway inhibitors. Sorafenib lead compound that has been recently approved by US FDA radioactive iodine-refractory differentiated cancer (DTC). clearly altering natural history DTC. In largest...
The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced metastatic urothelial carcinoma (mUC). Additional treatment were evaluated will be reported separately.Patients had mUC that progressed during following with a platinum-containing regimen....
<div>AbstractPurpose:<p>The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced metastatic urothelial carcinoma (mUC). Additional treatment were evaluated will be reported separately.</p>Patients Methods:<p>Patients had...
OBJECTIVE: To discuss an atypical presentation of a rare disease, neurolymphomatosis, with in depth review the literature and explanation our diagnostic approach. BACKGROUND: An acute inflammatory demyelinating polyneuropathy would be deemed this already very condition. In only 10-25[percnt] patients diagnosed Non-Hodgkin Lymphoma is there any nervous system involvement. Then out these 10-25[percnt], 0.1-2[percnt] will have described as direct infiltration tissue lymphomatous cells. The...
e22245 Background: Pemetrexed in combination with platinum chemotherapy is an indicated regimen for treatment of adv non-squamous NSCLC. The purpose this study to evaluate the efficacy pem-based patients (pts) NSCLC treated at West Virginia University Mary Babb Randolph Cancer Center (MBRCC). Methods: We retrospectively analyzed clinical data and outcome pts stage (IIIB/IV) who received our institution from 2009 2014. Results were compared published literature. Results: A total 74 included a...
Abstract Introduction: Social media has emerged as a formidable outlet for medical information through its vast global reach of individuals all educational levels and socioeconomic statuses but especially those in resource limited regions. However, misinformation presented universal challenge contributed to adverse outcomes. MedNews Week, virtual education platform, was developed combat misinformation, within hematology-oncology, contribute health by providing the mainstream public with free...
<p>Supplementary Figure 4. Swimlane plots of treatment and clinical response.</p>
<p>Supplementary Figure 1. MORPHEUS-UC study design and timing</p>
<p>Supplementary Figure 1. MORPHEUS-UC study design and timing</p>
<div>AbstractPurpose:<p>The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced metastatic urothelial carcinoma (mUC). Additional treatment were evaluated will be reported separately.</p>Patients Methods:<p>Patients had...